Home
|
Contact
|
Pharmacovigilance
|
Medical Information
|
ITA
ENG
Welcome to
Chiesi group
Enter at least 3 characters
About us
History
Mission and Values
Governance
Benefit Corporation and B Corp
Annual and Sustainability Report
Chiesi in the world
Main areas
Research and Development
Clinical Trial Transparency and Data Sharing
Chiesi Clinical Studies
Manufacturing plants
Partnering
Why Chiesi as a partner
Therapeutic Focus
Who we are
Where we are
Events
Open Innovation - The Impulse
Digital Health
Working at Chiesi
Sustainability
Our approach
Ethics and Transparency
Patients at the Center
Environment
Global Value Chain
Chiesi people
Communities
Media area
News
Press Release
Contact
Home
>
News & Events
>
News Corporate
Why Chiesi as a partner
Therapeutic Focus
Who we are
Where we are
Events
Open Innovation - The Impulse
Digital Health
January 2020
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
13/01/2020
DETAIL
August 2019
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
02/08/2019
DETAIL
May 2019
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
23/05/2019
DETAIL
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of...
30/05/2019
DETAIL
February 2019
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
04/02/2019
DETAIL
October 2018
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large...
02/10/2018
DETAIL
September 2018
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
03/09/2018
DETAIL
July 2018
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S....
24/07/2018
DETAIL
June 2018
Chiesi signs a deal with StartUp Health: first investment in the digital area
05/06/2018
DETAIL
March 2018
Global Corporate Development : opening of new offices in Boston
16/03/2018
DETAIL
October 2017
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development...
20/10/2017
DETAIL
June 2017
Chiesi Farmaceutici completes the acquisition of European Marketing Rights
23/06/2017
DETAIL
November 2016
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
21/11/2016
Parma
DETAIL
May 2016
Chiesi To Acquire 3 Hospital Products
10/05/2016
DETAIL
October 2013
PERSISTENT ASTHMA: THE INNOVATIVE INHALER AVIALABLE IN ITALY
09/10/2013
DETAIL
CHIESI ON THE WEB
Australia
Chiesi Australia
Austria
Chiesi Pharmaceuticals GmbH
Belgium
Chiesi SA/NV
Brazil
Chiesi Farmacêutica Ltda
Bulgaria
Chiesi Bulgaria EOOD
Canada
Chiesi Canada Corp
China
Chiesi Pharmaceutical (Shanghai) Co., Ltd
Czech Republic
Chiesi CZ s.r.o.
Denmark
Chiesi Pharma AB
Finland
Chiesi Pharma AB
France
Chiesi SAS
Germany
Chiesi GmbH
Greece
Chiesi Hellas Α.Ε.Β.Ε.
Hungary
Chiesi Hungary Kft.
Italy
CHIESI Italia S.p.A.
Japan
Chiesi Pharma Japan K.K.
Mexico
CHIESI MÉXICO
Norway
Chiesi Pharma AB
Pakistan
CHIESI PAKISTAN
Poland
Chiesi Poland
Romania
Chiesi România S.r.l.
Russian Federetion
Chiesi Pharmaceuticals LLC
Slovak Republic
Chiesi Slovakia s.r.o
Slovenia
Chiesi Slovenija, d.o.o
Spain
CHIESI ESPAÑA S.A.U
Sweden
Chiesi Pharma AB
The Netherlands
Chiesi Pharmaceuticals B.V.
Turkey
Chiesi İlaç Ticaret A.Ş
United Kingdom
Chiesi Limited
United States
Chiesi Usa, Inc.
